Skip to content
10-Q

Quarterly Report

Aegerion Pharmaceuticals, Inc.

0001558370-16-006027

← back to feed
Filed
May 16, 2016 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2016 · May 9, 2016 29.5M sh
Capex Q1 2016 · Mar 31, 2016 $524K
Capex Q1 2016 · Mar 31, 2015 $316K
Cash And Equivalents Q1 2016 · Mar 31, 2016 $42.72M
Cash And Equivalents Q1 2016 · Dec 31, 2015 $64.5M
Cash And Equivalents Q1 2016 · Mar 31, 2015 $67.38M
Cash And Equivalents Q1 2016 · Dec 31, 2014 $375.94M
Stockholders Equity Q1 2016 · Mar 31, 2016 $53.48M
Stockholders Equity Q1 2016 · Dec 31, 2015 $115.55M
Current Liabilities Q1 2016 · Mar 31, 2016 $110.4M
Current Liabilities Q1 2016 · Dec 31, 2015 $86.89M
Total Liabilities Q1 2016 · Mar 31, 2016 $346.95M
Total Liabilities Q1 2016 · Dec 31, 2015 $318.65M
Current Assets Q1 2016 · Mar 31, 2016 $147.14M
Current Assets Q1 2016 · Dec 31, 2015 $175.94M
Total Assets Q1 2016 · Mar 31, 2016 $400.42M
Total Assets Q1 2016 · Dec 31, 2015 $434.2M
Sga Expense Q1 2016 · Mar 31, 2016 $39.69M
Sga Expense Q1 2016 · Mar 31, 2015 $46.93M
Rd Expense Q1 2016 · Mar 31, 2016 $9.88M
Rd Expense Q1 2016 · Mar 31, 2015 $9.8M
Net Income Q1 2016 · Mar 31, 2016 −$65.55M
Net Income Q1 2016 · Mar 31, 2015 −$15.83M
Operating Income Q1 2016 · Mar 31, 2016 −$58.83M
Operating Income Q1 2016 · Mar 31, 2015 −$9.18M
Cost Of Revenue Q1 2016 · Mar 31, 2016 $14.97M
Cost Of Revenue Q1 2016 · Mar 31, 2015 $11.84M